Tyrosine
- Generic Name
- Tyrosine
- Brand Names
- Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO3
- CAS Number
- 60-18-4
- Unique Ingredient Identifier
- 42HK56048U
- Background
Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.
- Indication
Tyrosine is claimed to act as an effective antidepressant, however results are mixed. Tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies.
- Associated Conditions
- Acute Renal Dysfunction, Renal Failure, Chronic Renal Failure
- Associated Therapies
- Amino acid supplementation
A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Granulocyte-macrophage colony stimulating factor
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02327416
- Locations
- 🇨🇳
Beijing Youan Hospital, Beijing, Beijing, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
🇨🇳Xiangya Hospital, Central South University, Changsha, Hunan, China
A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC
- Conditions
- Lung Cancer
- Interventions
- Dietary Supplement: CurcuVIVA™
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Lady Davis Institute
- Target Recruit Count
- 20
- Registration Number
- NCT02321293
- Locations
- 🇨🇦
Peter Brojge Lung Cancer Center, Jewish General Hospital, Montreal, Quebec, Canada
Treatment of TNNT1-Myopathy With L-Tyrosine.
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 10
- Registration Number
- NCT02035501
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: VP -16Procedure: Stem Cell Infusion
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT01538472
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01460498
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
L-Tyrosine Supplementation in Patients With Fibromyalgia
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 15
- Registration Number
- NCT01219049
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3800
- Registration Number
- NCT01098500
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.